ADMA Biologics Inc. (ADMA)
ADMA Biologics Inc. (ADMA) Stock Price, Analysis & Data
| Bid | 6.44 |
| Market Cap | 2.19B |
| Revenue (ttm) | 512.28M |
| Net Income (ttm) | 168.96M |
| Beta | 0.77 |
| EPS (ttm) | 0.69 |
| PE Ratio (ttm) | 14.17 |
| Forward PE | 9.95 |
| P/B (ttm) | 5.82 |
| P/S (ttm) | 4.28 |
| Earnings Date | Nov 4, 2026 |
| Ask | 11.52 |
| Volume | 1,918,212 |
| Avg. Volume (20D) | 3,212,977 |
| Open | 9.83 |
| Previous Close | 9.90 |
| Day's Range | 9.76 - 9.96 |
| 52-Week Range | 7.21 - 20.46 |
| Analyst | Buy |
| Price Target | 17 (73.82%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ADMA
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodef...
Financial Performance
In 2025, ADMA Biologics's revenue was 510.17M, an increase of 19.63% compared to the previous year's 426.45M. Earnings were 146.93M, a decrease of -25.67%.
Financial StatementsAnalyst Forecast
According to 5 analyst ratings, the average rating for ADMA stock is "Buy". The 12-month stock price forecast is 17, which is upside of 73.82% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
